ReviewPharmaceutics2022
The Role of Intra-Patient Variability of Tacrolimus Drug Concentrations in Solid Organ Transplantation: A Focus on Liver, Heart, Lung and Pancreas.
Review in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical Impact of MeltDose Technology Extended-Release Tacrolimus (LCPT) in Solid Organ Transplantation: A Systematic Review.Drug design, development and therapy · 2026Pooled it
- Personalized tacrolimus therapy in allogeneic hematopoietic stem cell transplantation: from pharmacokinetic variability to novel control strategies.Journal of pharmaceutical health care and sciences · 2026Review
- Machine learning driven precision medicine in tacrolimus dosing: current research and future perspectives in liver and kidney transplantation.Frontiers in immunology · 2026Review
- Timing matters: tacrolimus intra-patient variability within the initial seven months forecastsFrontiers in immunology · 2026Article
- The predictive value of tacrolimus intrapatient variability and time in therapeutic range for renal transplant outcomes.Renal failure · 2025Article
- Association between tacrolimus intrapatient variability and clinical outcomes in kidney transplantation: a retrospective cohort study.Translational andrology and urology · 2025Article
- SARS-CoV-2 infection dynamics in a MHCI-mismatched lung transplant recipient.Nature communications · 2025Article
- Medication Adherence in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.Cancers · 2025Article
- Exploring the Association Between Intra-Patient Variability in Trough Concentration of Pazopanib and Clinical Outcomes in Renal Cell Carcinoma and Soft Tissue Sarcoma Patients.Clinical pharmacology and therapeutics · 2025Article
- Donor and recipient genetic variants in drug metabolizing enzymes and transporters affect early tacrolimus pharmacokinetics after liver transplantation.Scientific reports · 2025Article
- Article
- Time in therapeutic range of tacrolimus in allogeneic hematopoietic stem cell transplant recipients is associated with acute graft-versus-host disease prophylaxis.Scientific reports · 2025Article
- Comparing tacrolimus level monitoring in peripheral blood mononuclear cells and whole blood within one year after kidney transplantation: a single-center, prospective, observational study.Frontiers in pharmacology · 2025Article
- Fibrotic progression from acute cellular rejection is dependent on secondary lymphoid organs in a mouse model of chronic lung allograft dysfunction.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2024Article
- Tacrolimus Variability and Clinical Outcomes in the Early Post-lung Transplantation Period: Oral Versus Continuous Intravenous Administration.Clinical pharmacokinetics · 2024Article
- Pharmacokinetic assessment of tacrolimus in combination with deoxyschizandrin in rats.Frontiers in pharmacology · 2024Article
- Tacrolimus's Time Below Therapeutic Range Is Associated With Acute Pancreatic Graft Rejection and the Development ofTransplant international : official journal of the European Society for Organ Transplantation · 2024Article
- Clinical Effectiveness of Renal Transplant Outpatient Pharmaceutical Care Services in Korea.Healthcare (Basel, Switzerland) · 2023Article
- Impact of tacrolimus intra-patient variability in adverse outcomes after organ transplantation.World journal of transplantation · 2023Review
- Insights into the Pharmacogenetics of Tacrolimus Pharmacokinetics and Pharmacodynamics.Pharmaceutics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tacrolimus, the keystone immunosuppressive drug administered after solid organ transplantation, presents a narrow therapeutic index and wide inter- and intra-patient pharmacokinetic variability (IPV). The latter has been fairly studied in kidney transplantation, where it could impact outcomes. However, literature about other transplanted organ recipients remains inconclusive. This review aimed at summarizing the evidence about the IPV of tacrolimus concentrations outside of the scope of kidney transplantation. First, factors influencing IPV will be presented. Then, the potential of IPV as a biomarker predictive of graft outcomes will be discussed in liver, heart, lung and pancreas transplantation. Lastly, strategies to reduce IPV will be reviewed, with the ultimate objective being ready-to-implement solutions in clinical practice by transplantation professionals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.